VEGF inhibitors and vitrectomy for diabetic vitreoretinopathy

Developments in Ophthalmology

Volumn 44, Issue , 2009, Pages 69-81

  Cury Jr , Carlos E ^a   Rodrigues, Eduardo B ^a   Meyer, Carsten H ^b   Farah, Michel E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; DIABETIC RETINOPATHY; DRUG ANTAGONISM; HUMAN; METABOLISM; METHODOLOGY; TREATMENT OUTCOME; VITRECTOMY; VITREORETINOPATHY;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; HUMANS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE;

EID: 67651229377     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000223947     Document Type: Article

References (36)

1. Fong DS, Aiello L P, Gardner T W, et al: Retinopathy in diabetes. Diabetes Care 2004;27(suppl 1):84S-87S.
2. Preferred Practice Pattern: Diabetic Retinopathy. San Francisco, American Academy of Ophthalmology, 2003.
3. Aaberg TM, Abrams GW: Changing indications and techniques for vitrectomy in management of complications of diabetic retinopathy. Ophthalmology 1987;94:775-779.
4. Aaberg TM: Results of 100 consecutive vitrectomy procedures; in McPherson A (ed): Controversial Aspects of Vitreoretinal Surgery. St. Louis, Mosby, 1977, pp 245-249.
5. Yam JCS, Kwok AKH: Update on the treatment of diabetic retinopathy. Hong Kong Med J 2007;13:46- 60.
6. Ryan SJ: Retina. St Louis, Elsevier Mosby, 2006, vol 3, pp 1-1923.
7. Meyer CH: Current treatment approaches in diabetic macular edema. Ophthalmologica 2007;221: 118-131.
8. Lewis H, Abrams GW, Blumenkranz MS, Campo RV: Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992;99:753-759.
9. Sebag J, Buckingham B, Charles MA, Reiser K: Biochemical abnormalities of vitreous in humans with proliferative diabetic retinopathy. Arch Ophthalmol 1992;110:1472-476.
10. Pendergast SD: Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr Opin Ophthalmol 1998;9:71-75.
11. Tachi N, Ogino N: Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 1996;122:258-260.
12. Lewis H: The role of vitrectomy in the treatment of diabetic macular edema. Am J Ophthalmol 2001; 131:123-125.
13. Gandorfer A, Messmer EM, Ulbig M W, Kampik A: Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 2000;20:126-133.
14. Gandorfer A, Kampik A: Surgical removal of the internal limiting membrane in diabetic cystoid macular edema. Retina 2006;26:485-486.
15. Aiello L P, Avery RL, Arrigg PG, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
16. Tolentino MJ, Mcleod DS, Taomoto M, et al: Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-385.
17. Qaum T, Xu Q, Joussen AM, et al: VEGF-initiated bloodretinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-2413.
18. Stefánsson E: Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 2006;51: 364-380.
19. Emerson M V, Lauer AK: Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007;21:245-257.
20. Furlani BA, Meyer CH, Rodrigues EB, Maia M, Farah ME, Penha FM, Holz FG: Emerging pharma-cotherapies for diabetic macular edema. Expert Opin Emerg Drugs 2007;12:591-603.
21. Cunninghan ET Jr, Adamis AP, Altawell M, et al: Macugen diabetic retinopathy study group: a phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112:1747-1757.
22. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
23. Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthal Surg Lasers Imaging 2005;36:331-335.
24. Rosenfeld PJ, Fung AE, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthal Surg Lasers Imaging 2005;36:336-339.
25. Avery RL: Regression of retinal and iris neovascu-larization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354.
26. Mason JO, Albert MA, Vail R: Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006;26:356-357.
27. Haritoglou C, Kook D, Neubauer A: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999- 1005.
28. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Pan-American Collaborative Retina Study Group: Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American collaborative retina study group at 6-month follow-up. Ophthalmology 2007;114:743-750.
29. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF: Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-126.
30. Heier JS, Atoszik AN, Pavan PR, et al: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multi dose study. Ophthalmology 2006;113:642.E1-E4.
31. Chun DW, Heier JS, Topping TM, et al: A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113: 1706-1712.
32. Kroll P, Rodrigues EB, Hoerle S: Pathogenesis and classification of proliferative diabetic vitreoretinop-athy. Ophthalmologica 2007;221:78-94.
33. Smiddy WE, Flynn HW Jr: Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol 1999;43:491-507.
34. Rodrigues EB, Maia M, Meyer CH, Penha FM, Dib E, Farah ME: Vital dyes for chromovitrectomy. Curr Opin Ophthalmol 2007;18:179-187.
35. Chen E, Park CH: Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699-700.
36. Arevalo F, Maia M, Flynn Jr H W, Saravia M, Avery RL, Wu L, Farah ME, Pieramici DJ, Berrocal MH, Sanchez JG: Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy Br J Ophthalmol 2008;92:213-216.